Home Tags Ladiratuzumab vedotin

Tag: Ladiratuzumab vedotin

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development...

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize ladiratuzumab vedotin an investigational antibody-drug...

AACR 2018: Highlighting Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology

This year, the American Association for Cancer Research (AACR) will host their annual meeting April 14 - 18, 2018 in the McCormick Place North/South...

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...